Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival or ...

Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder ...

Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus ...

Patients with high-grade tumors, who don't respond to chemotherapy or immunotherapy drugs have a radical cystectomy—removal ...

Radical cystectomy with urinary diversion is the gold standard first-line treatment for muscle-invasive bladder cancer. Researchers from the University of Washington School of Medicine report that ...

FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes ...

The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the ...

Three-stage (group 2) 10 3.68 ± 0.55 Unilateral only 3.4 (MD) NS, baseline vs follow-up; NS group 1 vs 2 OE, prior cystectomy (group 2) 112 Not reported but all <6 cm 19.60 7.9 ± 4.2 Tubal ...

Median duration of response (DOR) was not reached. 92.4% cystectomy-free survival was observed and none of the patients with a complete response had undergone radical cystectomy or showed nodal or ...

Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with ...